TRANSGENE SA - MYVAC PLATFORM TO INITIATE PHASE 1 TRIAL IN SECOND INDICATION IN 2026
TRANSGENE SA - 3-YEAR DISEASE-FREE SURVIVAL FOLLOW-UP FOR HNSCC EXPECTED IN Q2/Q3 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.